<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurosci Appl</journal-id><journal-id journal-id-type="iso-abbrev">Neurosci Appl</journal-id><journal-id journal-id-type="pmc-domain-id">4773</journal-id><journal-id journal-id-type="pmc-domain">neurosciappl</journal-id><journal-title-group><journal-title>Neuroscience Applied</journal-title></journal-title-group><issn pub-type="epub">2772-4085</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12244215</article-id><article-id pub-id-type="pmcid-ver">PMC12244215.1</article-id><article-id pub-id-type="pmcaid">12244215</article-id><article-id pub-id-type="pmcaiid">12244215</article-id><article-id pub-id-type="pmid">40656113</article-id><article-id pub-id-type="doi">10.1016/j.nsa.2024.104094</article-id><article-id pub-id-type="pii">S2772-4085(24)00159-5</article-id><article-id pub-id-type="publisher-id">104094</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>Neurovascular coupling of striatal dopamine D<sub>2/3</sub> receptor availability and perfusion using simultaneous PET/MR in humans</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Schmitz</surname><given-names initials="CN">Christian N.</given-names></name><email>christian.schmitz@zi-mannheim.de</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Hart</surname><given-names initials="XM">Xenia M.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Spangemacher</surname><given-names initials="M">Moritz</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Roth</surname><given-names initials="JL">Jana L.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Lazarevic</surname><given-names initials="I">Ivana</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Oberth&#252;r</surname><given-names initials="G">Gunilla</given-names></name><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>B&#252;sing</surname><given-names initials="KA">Karen A.</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Becker</surname><given-names initials="R">Robert</given-names></name><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Cumming</surname><given-names initials="P">Paul</given-names></name><xref rid="aff8" ref-type="aff">h</xref><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Gr&#252;nder</surname><given-names initials="G">Gerhard</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><aff id="aff1"><label>a</label>Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany</aff><aff id="aff2"><label>b</label>Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany</aff><aff id="aff3"><label>c</label>Clinic for Radiology and Nuclear Medicine, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany</aff><aff id="aff4"><label>d</label>Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany</aff><aff id="aff5"><label>e</label>Center for Innovative Psychiatry and Psychotherapy Research (ZIPP), Central Institute of Mental Health, Mannheim, Germany</aff><aff id="aff6"><label>f</label>German Center for Mental Health (DZPG), Partner Site Mannheim, Germany</aff><aff id="aff7"><label>g</label>Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan</aff><aff id="aff8"><label>h</label>Department of Nuclear Medicine, Bern University Hospital, Freiburgstra&#223;e 18, 3010, Bern, Switzerland</aff><aff id="aff9"><label>i</label>School of Psychology and Counselling, Queensland University of Technology, Brisbane, QLD, 4059, Australia</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. Central Institute of Mental Health, University of Heidelberg, J5, 68159, Mannheim, Germany. <email>christian.schmitz@zi-mannheim.de</email></corresp></author-notes><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>05</day><month>10</month><year>2024</year></pub-date><volume>3</volume><issue-id pub-id-type="pmc-issue-id">492663</issue-id><elocation-id>104094</elocation-id><history><date date-type="received"><day>13</day><month>5</month><year>2024</year></date><date date-type="rev-recd"><day>2</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>4</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>10</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>11</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-14 15:25:24.943"><day>14</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 The Authors</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>The midbrain dopamine system contributes to important neural functions in the basal ganglia, and is involved in aspects of pathological processes in schizophrenia. In preclinical and clinical studies, pharmacological blockade or stimulation of brain dopamine receptors alters cerebral perfusion, which is a surrogate marker of metabolic activity. However, there is scant documentation of this neurofunctional coupling in relation to individual differences in the dopamine system of healthy humans. We therefore tested the hypothesis that baseline dopamine D<sub>2/3</sub> receptor availability predicts individual blood flow responses to challenge with a dopamine agonist.</p><p>We used [<sup>18</sup>F]fallypride positron emission tomography (PET) imaging to quantify dopamine D<sub>2/3</sub> receptor availability as binding potential (BP<sub>ND</sub>) in nine healthy subjects. Using simultaneous perfusion-weighted functional magnetic resonance imaging (fMRI), we measured perfusion at baseline and after challenge with the dopamine agonist apomorphine.</p><p>Results of this multimodal imaging study revealed a strong negative association between baseline D<sub>2/3</sub> dopamine receptor availability and apomorphine-induced perfusion changes in the human basal ganglia. There was considerable intra-individual variation in the neurovascular response to the apomorphine challenge, which may call for further investigation of the dopaminergic regulation of cerebral perfusion in patients with schizophrenia.</p><p>This study describes a novel paradigm for assessing dopamine sensitivity, facilitating an exploration of the dopamine supersensitivity hypothesis.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Dopamine</kwd><kwd>PET</kwd><kwd>Perfusion</kwd><kwd>pcASL</kwd><kwd>fMRI</kwd><kwd>Human</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><notes><p id="misc0010">Handling Editor: Prof. A. Meyer-Lindenberg</p></notes></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">The midbrain dopamine (DA) system is a major therapeutic target in diverse conditions such as schizophrenia, attention deficit hyperactivity disorder (ADHD), substance use disorders, and Parkinson's disease. There is broad clinical use of pharmaceuticals that modulate DA transmission, notably antipsychotic drugs (<xref rid="bib18" ref-type="bibr">Efthimiou et al., 2024</xref>), psychostimulants (<xref rid="bib7" ref-type="bibr">Caravaggio et al., 2021</xref>), and dopamine agonists (<xref rid="bib16" ref-type="bibr">Dhall and Kreitzman, 2016</xref>; <xref rid="bib48" ref-type="bibr">Scarselli et al., 2001</xref>). In recent decades, molecular imaging by positron emission tomography (PET), single photon computer tomography (SPECT) (<xref rid="bib12" ref-type="bibr">Cumming, 2009</xref>), and functional magnetic resonance imaging (fMRI) (<xref rid="bib5" ref-type="bibr">Bruinsma et al., 2018</xref>) have emerged as mature tools for investigating various aspects of cerebral DA in humans. The advent of multimodal PET/MRI imaging affords new prospects for probing relationships between neurotransmission and brain function changes (reviewed by (<xref rid="bib47" ref-type="bibr">Sander et al., 2020</xref>)). However, there are relatively few multimodal imaging studies aiming to link DA markers with functional changes in brain activity (reviewed by (<xref rid="bib6" ref-type="bibr">Calabro et al., 2023</xref>)).</p><p id="p0015">Apomorphine is a non-selective DA receptor agonist with affinity for all DA receptor subtypes, which is known clinically for its transient efficacy in alleviating motor symptoms of Parkinson's disease (reviewed by (<xref rid="bib30" ref-type="bibr">Jenner and Katzenschlager, 2016</xref>)). In a pre-PET era study, challenge with apomorphine increased regional cerebral blood flow (rCBF) in rat brain to the [<sup>14</sup>C]iodoantipyrine autoradiographic method (<xref rid="bib27" ref-type="bibr">Ingvar et al., 1983</xref>). Nguyen et al. confirmed and extended this result in a pharmaco-fMRI rat study with apomorphine and amphetamine challenges (<xref rid="bib38" ref-type="bibr">Nguyen et al., 2000</xref>). In a human single photon emission tomography (SPECT) study, apomorphine treatment increased rCBF in patients with Parkinson's disease, with the caveat that pretreatment with the putatively peripherally-acting antagonist domperidone blocked the effect (<xref rid="bib45" ref-type="bibr">Sabatini et al., 1991</xref>). Conversely, administration of the DA D<sub>2/3</sub> receptor (D<sub>2/3</sub>R) antagonist [<sup>11</sup>C]raclopride at a pharmacological dose evoking substantial receptor occupancy to PET increased cerebral blood volume to functional magnetic resonance imaging (fMRI) in nonhuman primate brain (<xref rid="bib46" ref-type="bibr">Sander et al., 2013</xref>). In another preclinical fMRI study, direct optogenetic stimulation of DA neurons in the rat ventral tegmental area (VTA) increased the blood oxygenation level dependent (BOLD) signal of VTA-innervated limbic regions, including the ventral striatum (<xref rid="bib34" ref-type="bibr">Lohani et al., 2017</xref>). Thus, a considerable body of evidence indicates that D<sub>2/3</sub>R signaling contributes to cerebrovascular regulation.</p><p id="p0020">While BOLD contrast-based fMRI techniques tend to manifest baseline drift of the signal (<xref rid="bib63" ref-type="bibr">Yan et al., 2009</xref>), arterial spin labelling (ASL) provides a more temporally stable reading of brain hemodynamic changes (<xref rid="bib2" ref-type="bibr">Alsop et al., 2015</xref>). Thus, available results suggest that multimodal imaging of D<sub>2/3</sub>R availability to PET and cerebral perfusion to ASL-fMRI provide a valuable readout to evaluate the functional state in human brain.</p><p id="p0025">Given this background, we used a hybrid PET/MR system to measure D<sub>2/3</sub>R availability to the antagonist ligand [<sup>18</sup>F]fallypride (FA), in conjunction with ASL measurements in a group of nine healthy participants. We thus applied pharmaco-PET/fMRI to test the hypothesis of dopamine sensitivity that baseline D<sub>2/3</sub>R availability in the striatum predicts baseline rCBF and individual apomorphine-induced changes in rCBF. As a secondary hypothesis, we tested for dopamine sensitivity also in the striatal subregions, as well as the thalamus and ITG. As such, we introduce a new methodology for investigating neurovascular coupling of the DA system in human brain using simultaneous PET/MR imaging.</p></sec><sec id="sec2"><label>2</label><title>Materials and methods</title><p id="p0030">The local ethics committee of the Medical Faculty Mannheim of the University of Heidelberg (Mannheim, Germany) and the German Federal Office for Radiation Protection approved this investigation. We conducted the study in strict accordance with the ethical standards laid down in the 1964 Declaration of Helsinki in its most recent revision. All subjects gave written informed consent. All PET investigations were performed at the ZIPP core facility of the Central Institute of Mental Health Mannheim, Germany. This study has been registered at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="intref0010">ClinicalTrials.gov</ext-link> as part of a larger study (ID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03911726">NCT03911726</ext-link>).</p><sec id="sec2.1"><label>2.1</label><title>Subjects and study procedure</title><p id="p0035">We initially recruited a group of 12 healthy subjects (six males and six females of mean&#160;&#177;&#160;SD age 33.8&#160;&#177;&#160;9.0 years (range 23&#8211;49 years). One participant experienced shivering and nausea as transient side effects associated with the pharmacological intervention, and had to be excluded from the study. We also excluded data of two other participants because of technical errors in the fMRI sessions. The analysis thus included nine healthy participants (four males and five females of mean&#160;&#177;&#160;SD age 34.6&#160;&#177;&#160;9.7 years (range 24&#8211;49 years). Detailed demographic data of the subjects are provided in <xref rid="tbl1" ref-type="table">Table 1</xref> (and <xref rid="appsec1" ref-type="sec">Supplementary Table 1</xref> for all 12 participants).<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Demographic data of the included healthy subjects.</p></caption><alt-text id="alttext0025">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Parameter</th><th colspan="1" rowspan="1">Healthy Subjects (n&#160;=&#160;9)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="left" colspan="1" rowspan="1">34.6 (&#177;9.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Weight (kg)</td><td align="left" colspan="1" rowspan="1">74.2 (&#177;14.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Education (years)</td><td align="left" colspan="1" rowspan="1">13.0 (&#177;0.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Gender (m/f)</td><td align="left" colspan="1" rowspan="1">4/5</td></tr><tr><td align="left" colspan="1" rowspan="1">Handiness (right/left handed)</td><td align="left" colspan="1" rowspan="1">9/0</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoker status (non-smoker/smoker)</td><td align="left" colspan="1" rowspan="1">9/0</td></tr></tbody></table></table-wrap></p><p id="p0040">All subjects were German-speakers with no evident speech pathology. Inclusion criteria consisted of non-pathological findings in standard laboratory parameters (electrolytes, liver parameters, creatine kinase, TSH, small blood count), electrocardiogram, as well as negative urine tests for substances of abuse (cannabis, amphetamines, cocaine, and opiates) on the days of screening and imaging. A pregnancy test at screening and just prior to imaging was mandatory for female subjects. All participants were carefully screened for presence of any psychiatric exclusion criterion using a structured diagnostic interview (<bold>Mini</bold> International Neuropsychiatric Interview (<bold>M.I.N.I.</bold>) for relevant DSM-5 axis I disorders (<xref rid="bib52" ref-type="bibr">Sheehan et al., 1998</xref>). All subjects received compensation (300 Euro) for inconvenience arising from their participation.</p><p id="p0045">All participants were under medical supervision during the PET recording and for at least additional 30&#160;min thereafter.</p></sec><sec id="sec2.2"><label>2.2</label><title>Pharmacological challenge</title><p id="p0050">Apomorphine is a partially selective DA receptor agonist, with higher affinity for D<sub>2/3</sub>Rs as compared to dopamine D<sub>1</sub> receptors (<xref rid="bib48" ref-type="bibr">Scarselli et al., 2001</xref>; <xref rid="bib36" ref-type="bibr">Millan et al., 2002</xref>). Following earlier investigations of its effects on neurovascular coupling of DA D<sub>2/3</sub>Rs, we applied apomorphine (0.01&#160;mg/kg body weight, s. c.), a dose affecting brain dopamine synthesis to PET, without pronounced side effects such as nausea (<xref rid="bib29" ref-type="bibr">Jauhar et al., 2017</xref>).</p></sec><sec id="sec2.3"><label>2.3</label><title>Imaging</title><p id="p0055">All patients underwent MRI on a high-resolution Siemens Biograph mMR (Siemens Healthineers, Germany), equipped with a 32 channel head coil. The MRI protocol included a structural T1 weighted image (MPRAGE) and perfusion weighted imaging sequences during the PET recording. T1-weighted structural images were obtained with a repetition time (TR) of 2&#160;s, echo time (TE)&#160;=&#160;2.58 ms, flip angle&#160;=&#160;10&#176;, 192 slices, slice thickness&#160;=&#160;0.9&#160;mm, voxel dimensions&#160;=&#160;0.4&#160;mm&#160;&#215;&#160;0.4&#160;mm&#160;&#215;&#160;0.9&#160;mm, FoV&#160;=&#160;230&#160;mm.</p></sec><sec id="sec2.4"><label>2.4</label><title>Radiochemistry and PET data acquisition</title><p id="p0060">To measure D<sub>2/3</sub>R availability in the brain, we used the benzamide antagonist radioligand [<sup>18</sup>F]fallypride ([<sup>18</sup>F]FP), which was prepared in a high-yield modification of the radiosynthesis method for [<sup>18</sup>F]desmethoxyfallypride (<xref rid="bib24" ref-type="bibr">Gr&#252;nder et al., 2003</xref>; <xref rid="bib58" ref-type="bibr">Vernaleken et al., 2013</xref>). Quality control of [<sup>18</sup>F]FP before administration entailed determination of chemical and radiochemical purity, molar activity, and pH.</p><p id="p0065">PET data were acquired as dynamic emission images in 3D-mode (LR field-of-view 50&#160;cm, AP FOV 26.55&#160;cm). We injected a mean&#160;&#177;&#160;SD activity of 211&#160;&#177;&#160;14&#160;MBq [<sup>18</sup>F]FP over 30&#160;s into the cubital vein of the left arm. The corrected molar activity was 109&#160;&#177;&#160;34 (range 54&#8211;152) GBq/&#956;mol, corresponding to&#160;&lt;&#160;1&#160;nmol fallypride mass injected in each case. The injected activity did not significantly correlate with the BP<sub>ND</sub> measured in any region of interest (ROI). Dynamic emission data were acquired during 210&#160;min in a recording split into three consecutive blocks: 53.5&#160;min of emission data, a 25-min break, 40&#160;min of emission data, another 25-min break, and a final 60&#160;min of emission data. Data was acquired as a series of up to 29-time frames (6 &#8727; 10&#160;s, 3 &#8727; 20&#160;s, 3 &#8727; 1&#160;min, 3 &#8727; 2&#160;min, 2 &#8727; 5&#160;min, and 13 &#8727; 10&#160;min, adapted from <xref rid="bib54" ref-type="bibr">Slifstein et al. (2010)</xref> for the provision of an intermittent scanning-protocol; see <xref rid="fig1" ref-type="fig">Fig. 1</xref>, a). Data were reconstructed with an attenuation correction using an iterative high-resolution Flash 3D Vibe sequence with six iterations, based on a calculated MR-attenuation map (<xref rid="bib35" ref-type="bibr">Martinez-et al., 2009</xref>). Each MR-AC map was resampled to PET resolution as part of the reconstruction, without additional filtering.<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>A) Experimental design: Representative time activity curves of the PET acquisition for the bilateral regions: putamen (Put), caudate nucleus (CN), thalamus, inferior temporal cortex (ITC) and cerebellum (Cer). The start of each time frame of the PET acquisition is denoted as tick on the horizontal axis. The time point of the administration of the dopamine agonist apomorphine is depicted as vertical dotted line. Periods of the perfusion weighted image acquisitions (ASL) are marked in dark grey. Inter-session pauses of PET-acquisition are marked in light grey, the signal of the inter-session pauses is based on linear interpolation.</p><p>b) Representative parametric maps fused with a structural T1-weighted MR MNI152 NLIN 6th generation template (1), fusion parametric map of the dopamine receptor D<sub>2/3</sub> binding potential combined with the structural T1-weighted MR MNI152 template (2) and fusion parametric map of cerebral blood flow combined with the structural T1-weighted MR MNI152 template (3).</p></caption><alt-text id="alttext0015">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec2.5"><label>2.5</label><title>PET image processing</title><p id="p0070">The dynamic PET-data was analyzed in the PMOD image analysis suite (PNEURO, PMOD Technologies LLC, Z&#252;rich, Schweiz, Version 4.4). Using a normalized mutual information algorithm as a dissimilarity function, we transformed each of the post-break segments of PET acquisition to match the T1-weighted MR-image of the first session. The concatenated dynamic PET image was denoised (Fast Non-Local Means (NLM)), motion corrected, and co-registered to the T1-weighted MR image of the first session. In cases of moderate head movement (interpolated session-breaks excluded), we performed frame-wise motion correction using a sequential registration procedure beginning with all frames spanning more than 1&#160;min, while assuming no relevant head motion during the first 2&#160;min of the recording. Upon using a Gaussian filter with a kernel of 6&#160;mm and a squared difference sum as error function, we visually inspected the registration results by comparing outlines of the brain surface and of the striatal ROIs (caudate nucleus and putamen). The T1-weighted MR image was separately denoised with a fast Non-Local Means (NLM) algorithm, segmented into three probability maps (representing grey matter, white matter, and CSF), and normalized to the standard template (MNI152 NLIN 6th generation template).</p><p id="p0075">We extracted time activity curves (TACs) from the preprocessed PET data using templates of polygonal ROIs applied to the spatially normalized dynamic recordings (<xref rid="bib56" ref-type="bibr">Vernaleken et al., 2008</xref>, <xref rid="bib57" ref-type="bibr">2010</xref>, <xref rid="bib58" ref-type="bibr">2013</xref>). The bilateral brain regions of interest (ROIs) for putamen, caudate nucleus, thalamus, and inferior temporal cortex (ITC) were derived from the structural Harvard-Oxford atlas (<xref rid="bib22" ref-type="bibr">Goldstein et al., 2007</xref>). A probabilistic cerebellar atlas served for extraction of the reference tissue TAC (<xref rid="bib17" ref-type="bibr">Diedrichsen et al., 2011</xref>) (<xref rid="fig1" ref-type="fig">Fig. 1</xref>, a).</p><p id="p0080">There was no discernible [<sup>18</sup>F]FP displacement after apomorphine treatment (<xref rid="fig1" ref-type="fig">Fig. 1</xref>, a) in accordance with <xref rid="bib15" ref-type="bibr">Deutschl&#228;nder et al. (2016)</xref>, who saw no significant [<sup>18</sup>F]FP displacement in striatum of Parkinson's disease patients upon treatment with the DA agonist pramipexole. We calculated [<sup>18</sup>F]FP BP<sub>ND</sub> of the respective ROIs using the simplified reference tissue model (SRTM), with cerebellum as the reference region (<xref rid="bib33" ref-type="bibr">Lammertsma and Hume, 1996</xref>), using TACs terminating at 160&#160;&#177;&#160;4&#160;min after tracer injection, i.e., just prior to the apomorphine administration. The cerebellum is validated and widely established as a reference region for [<sup>18</sup>F]FP BP<sub>ND</sub> calculation by SRTM (<xref rid="bib58" ref-type="bibr">Vernaleken et al., 2013</xref>; <xref rid="bib13" ref-type="bibr">Cumming et al., 2013</xref>; <xref rid="bib28" ref-type="bibr">Ishibashi et al., 2013</xref>), with the caveat that it contains a small D<sub>2/3</sub>R binding component (<xref rid="bib25" ref-type="bibr">Hall et al., 1996</xref>). Based on prior studies, we expect a 5% bias in the estimation of striatal [<sup>18</sup>F]FA BP<sub>ND</sub> arising from the cerebellum binding component (<xref rid="bib24" ref-type="bibr">Gr&#252;nder et al., 2003</xref>; <xref rid="bib39" ref-type="bibr">Olsson et al., 2004</xref>). Following the method of <xref rid="bib42" ref-type="bibr">Rousset et al., 1998</xref>, <xref rid="bib43" ref-type="bibr">2000</xref>, w e applied partial volume correction (PVC) of the selected brain TACs for the kinetic modelling.</p></sec><sec id="sec2.6"><label>2.6</label><title>Perfusion weighted imaging data acquisition</title><p id="p0085">To evaluate the hemodynamic changes induced by the apomorphine challenge, we used a 5-post-labelling delay, pseudo-continuous arterial spin labeling (pcASL) protocol for perfusion-weighted imaging with background suppressed GRASE readout (<xref rid="bib59" ref-type="bibr">Wang et al., 2013</xref>). Our protocol followed Alsop's white paper on the approach (<xref rid="bib2" ref-type="bibr">Alsop et al., 2015</xref>); labeling pulse duration&#160;=&#160;1.8&#160;s, PLD&#160;=&#160;0.5/1/1.5/2/2.5&#160;s, TR&#160;=&#160;2.5/3/3.5/4/4.5&#160;s, FOV&#160;=&#160;24&#160;cm, matrix&#160;=&#160;64&#160;&#215;&#160;64, 40&#160;&#215;&#160;3&#160;mm slices, rate-2 GRAPPA factor&#160;=&#160;2, TE&#160;=&#160;45.46 ms, 8 pairs of tag and control for each delay, total scan time 11&#160;min 53&#160;s. The M0 calibration image was acquired with a TR of 4.4&#160;s and otherwise analogous settings. The pcASL acquisition was performed twice per imaging session, i.e., immediately before and approximately 14&#160;min after the apomorphine challenge. We selected these periods due to the pharmacokinetics of s. c. Apomorphine, which has a median time to maximum plasma concentration (T<sub>max</sub>) of 15&#8211;23&#160;min (<xref rid="bib1" ref-type="bibr">Agbo et al., 2021</xref>). We selected the multi-delay sequence based on its 15% lower error in rCBF estimation compared to a single&#8208;PLD sequence (<xref rid="bib62" ref-type="bibr">Woods et al., 2019</xref>). The labeling plane of the sequence was positioned with the recommended 90&#160;mm distance from the center of imaging slices to the labeling plane perpendicular to the carotid and vertebral arteries. Due to the limited field of view of the sequence, parietal cortical areas were not included in the ASL acquisition. The analysis of the perfusion-weighted imaging was performed with the FSL toolbox Bayesian Inference for Arterial Spin Labeling MRI, BASIL (<xref rid="bib8" ref-type="bibr">Chappell et al., 2009</xref>; <xref rid="bib23" ref-type="bibr">Groves et al., 2009</xref>), using the PVC of <xref rid="bib9" ref-type="bibr">Chappell et al. (2011)</xref>, as required by the vulnerability of striatal fMRI signals to spillover. A similar analysis was performed for the average global grey and white matter voxel signals of brain perfusion, namely gCBFpre (before the pharmacological challenge) and gCBFpost (after the pharmacological challenge). These signals were compared using a paired <italic toggle="yes">t</italic>-test.</p></sec><sec id="sec2.7"><label>2.7</label><title>Perfusion image processing</title><p id="p0090">Pharmacologically induced relative rCBF changes were determined by subtraction of the ROI-specific rCBF before and after the pharmacological challenge, with normalization to the baseline perfusion rCBFpre: &#916;rCBF<sub>ROI</sub> = (rCBFpost<sub>ROI</sub> &#8211; rCBFpre<sub>ROI</sub>)/rCBFpre<sub>ROI</sub>.</p></sec><sec id="sec2.8"><label>2.8</label><title>Multimodal analysis</title><p id="p0095">BP<sub>ND</sub> and &#916;rCBF values were extracted for each ROI. We used the Pearson correlation for comparison of regional BP<sub>ND</sub> and &#916;rCBF values, with significance level set at p&#160;=&#160;0.05. The primary hypothesis focused on investigating BP<sub>ND</sub> and &#916;rCBF in the striatum. For the striatal subregions, as well as the thalamus and ITG, BP<sub>ND</sub> and &#916;rCBF were tested as secondary hypotheses. Multiple comparisons for the secondary hypotheses were corrected using the false discovery rate proposed by <xref rid="bib3" ref-type="bibr">Benjamini and Hochberg (1995)</xref>. We confirmed homoscedasticity and normality of the data with Levene's and Shapiro's tests, respectively. Median values of the ROI's BP<sub>ND</sub> and &#916;rCBF values served for the further analyses.</p></sec><sec id="sec2.9"><label>2.9</label><title>Physiological recording</title><p id="p0100">To account for potential apomorphine-induced changes in heart rate and respiration rate, we used the patient monitoring unit (PMU) of the Siemens Biograph mMR (Siemens Healthineers, Germany). Based on custom-written code, we derived the average heart and respiration rates at baseline before the administration of the dopamine agonist and at 19&#160;min after administration, which we compared by paired <italic toggle="yes">t</italic>-test.</p></sec><sec id="sec2.10"><label>2.10</label><title>Code availability</title><p id="p0105">The dynamic PET-data were analyzed using the PMOD image analysis suite (PNEURO, PMOD Technologies LLC, Z&#252;rich, Schweiz, Version 4.4). In-house bash scripts for the analysis of the perfusion-weighted imaging based on the FSL toolbox Bayesian Inference for Arterial Spin Labeling MRI (BASIL), as well as Python codes for the statistical and correlation analysis and illustration of results are available upon request.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><p id="p0110">The final study group consisted of nine participants (four males, five females) of mean&#160;&#177;&#160;SD age 35&#160;&#177;&#160;10 years, and 13&#160;&#177;&#160;3 years of education. All were right-handed and non-smokers.</p><sec id="sec3.1"><label>3.1</label><title>[<sup>18</sup>F]FA BP<sub>ND</sub> in healthy subjects</title><p id="p0115">We summarize our experimental design, and present mean parametric maps and representative brain TACs in <xref rid="fig1" ref-type="fig">Fig. 1</xref>. There were no significant left-right asymmetries; mean&#160;&#177;&#160;SD BP<sub>ND</sub> for the bilateral structures were 47.9&#160;&#177;&#160;4.0 in striatum (i.e., caudate-putamen), 50.5&#160;&#177;&#160;6.7 in caudate nucleus, 44.0&#160;&#177;&#160;4.5 in putamen, 3.2&#160;&#177;&#160;0.5 in thalamus, and 1.9&#160;&#177;&#160;0.5 in ITC (<xref rid="tbl2" ref-type="table">Table 2</xref>). There were a no significant correlations between striatal BP<sub>ND</sub> and age (r&#160;=&#160;&#8722;0.3, p&#160;=&#160;0.44), nor were there any associations of striatal BP<sub>ND</sub> and sex (r&#160;=&#160;&#8722;0.4, p&#160;=&#160;0.29) or the administered tracer dose (r&#160;=&#160;&#8722;0.2, p&#160;=&#160;0.61).<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Dopamine D<sub>2/3</sub> receptor availability (BP<sub>ND</sub>) with partial volume correction, regional baseline perfusion (rCBF) and apomorphine-induced perfusion changes (&#916;rCBF) in the bilateral striatum, caudate nucleus (CN), putamen (Put), thalamus (Thal) and inferior temporal cortex (ITC) regions of interest (ROI) in (N&#160;=&#160;9) healthy controls. P-values for the regions specified in the primary hypothesis are presented both with (p<sub>FDR</sub>) and without (p<sub>uncorrected</sub>) multiple comparison corrections, using the Benjamini and Hochberg method (<xref rid="bib3" ref-type="bibr">Benjamini and Hochberg, 1995</xref>). Statistically significant values are marked with an asterisk (&#8727;).</p></caption><alt-text id="alttext0030">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">ROI</th><th colspan="2" rowspan="1">D<sub>2/3</sub> binding potential<hr/></th><th colspan="2" rowspan="1">rCBF<hr/></th><th colspan="4" rowspan="1">&#916;rCBF<hr/></th></tr><tr><th colspan="1" rowspan="1">BP<sub>ND</sub></th><th colspan="1" rowspan="1">SD</th><th colspan="1" rowspan="1"><inline-formula><mml:math id="M1" altimg="si1.svg"><mml:mrow><mml:mfrac><mml:mtext>mL</mml:mtext><mml:mrow><mml:mn>100</mml:mn><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">g</mml:mi><mml:mo>&#8727;</mml:mo><mml:mi>min</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula></th><th colspan="1" rowspan="1">SD</th><th colspan="1" rowspan="1">&#916;</th><th colspan="1" rowspan="1">SD</th><th colspan="1" rowspan="1">p<sub>FDR</sub></th><th colspan="1" rowspan="1">p<sub>uncorrected</sub></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><bold>Striatum</bold></td><td align="left" colspan="1" rowspan="1">46.9</td><td align="left" colspan="1" rowspan="1">4.0</td><td align="left" colspan="1" rowspan="1">61.1</td><td align="left" colspan="1" rowspan="1">24.3</td><td align="left" colspan="1" rowspan="1">8.08%</td><td align="left" colspan="1" rowspan="1">0.21</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.182</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>CN</bold></td><td align="left" colspan="1" rowspan="1">50.5</td><td align="left" colspan="1" rowspan="1">6.7</td><td align="left" colspan="1" rowspan="1">58.4</td><td align="left" colspan="1" rowspan="1">20.2</td><td align="left" colspan="1" rowspan="1">9.28%</td><td align="left" colspan="1" rowspan="1">0.25</td><td align="left" colspan="1" rowspan="1">0.108</td><td align="left" colspan="1" rowspan="1">0.027</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Put</bold></td><td align="left" colspan="1" rowspan="1">42.4</td><td align="left" colspan="1" rowspan="1">4.8</td><td align="left" colspan="1" rowspan="1">79.9</td><td align="left" colspan="1" rowspan="1">31.5</td><td align="left" colspan="1" rowspan="1">6.87%</td><td align="left" colspan="1" rowspan="1">0.24</td><td align="left" colspan="1" rowspan="1">0.606</td><td align="left" colspan="1" rowspan="1">0.303</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Thal</bold></td><td align="left" colspan="1" rowspan="1">3.18</td><td align="left" colspan="1" rowspan="1">0.46</td><td align="left" colspan="1" rowspan="1">70.0</td><td align="left" colspan="1" rowspan="1">27.6</td><td align="left" colspan="1" rowspan="1">23.0%</td><td align="left" colspan="1" rowspan="1">0.21</td><td align="left" colspan="1" rowspan="1">0.627</td><td align="left" colspan="1" rowspan="1">0.470</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>ITC</bold></td><td align="left" colspan="1" rowspan="1">1.87</td><td align="left" colspan="1" rowspan="1">0.45</td><td align="left" colspan="1" rowspan="1">54.7</td><td align="left" colspan="1" rowspan="1">21.1</td><td align="left" colspan="1" rowspan="1">&#8722;3.9%</td><td align="left" colspan="1" rowspan="1">0.25</td><td align="left" colspan="1" rowspan="1">0.743</td><td align="left" colspan="1" rowspan="1">0.743</td></tr></tbody></table></table-wrap></p></sec><sec id="sec3.2"><label>3.2</label><title>Apomorphine-induced rCBF changes</title><p id="p0120">There was no significant lateralization of baseline rCBF measures. At baseline, the average&#160;&#177;&#160;SD bilateral rCBF (mL/(100&#160;g&#8727;min)) was 61.1&#160;&#177;&#160;24.3 in entire striatum, 58.4&#160;&#177;&#160;20.2 in caudate nucleus, 79.9&#160;&#177;&#160;31.5 in putamen, 70.0&#160;&#177;&#160;27.6 in thalamus, and 54.7&#160;&#177;&#160;21.1 in ITC. After administration of apomorphine, there was no significant perfusion increase (&#916;rCBF) in bilateral caudate-putamen (8.1&#160;&#177;&#160;21%; p<sub>uncorrected</sub>&#160;=&#160;0.18). To exploratory analysis, there was a 9.3&#160;&#177;&#160;25% increase in bilateral caudate nucleus that did not survive correction for multiple comparisons (p<sub>uncorrected</sub>&#160;=&#160;0.027; p<sub>FDR</sub>&#160;=&#160;0.11), and a non-significant 6.87&#160;&#177;&#160;24% increases in putamen (p<sub>FDR</sub>&#160;=&#160;0.61), a non-significant 3.0&#160;&#177;&#160;21% rCBF increase in bilateral thalamus (p<sub>FDR</sub>&#160;=&#160;0.63), and a non-significant 3.9&#160;&#177;&#160;25% decrease in bilateral ITC (p<sub>FDR</sub>&#160;=&#160;0.74) based on a paired <italic toggle="yes">t</italic>-test (<xref rid="tbl2" ref-type="table">Table 2</xref>).</p></sec><sec id="sec3.3"><label>3.3</label><title>Apomorphine-induced rCBF changes in caudate-putamen correlate with the [<sup>18</sup>F]FP BP<sub>ND</sub></title><p id="p0125">Pearson's correlation analysis showed significant negative correlations between [<sup>18</sup>F]FP BP<sub>ND</sub> and &#916;rCBF in the bilateral striatum (r&#160;=&#160;&#8722;0.71, p<sub>uncorrected</sub>&#160;=&#160;0.033), caudate nucleus (r&#160;=&#160;&#8722;0.64, p<sub>FDR</sub>&#160;=&#160;0.008), and thalamus (r&#160;=&#160;&#8722;0.66, p<sub>FDR</sub>&#160;=&#160;0.008). There were no significant correlations in putamen (r&#160;=&#160;&#8722;0.068, p<sub>FDR</sub>&#160;=&#160;0.79), or the ITC (r&#160;=&#160;&#8722;0.20, p<sub>FDR</sub>&#160;=&#160;0.79) (<xref rid="fig2" ref-type="fig">Fig. 2</xref>, <xref rid="tbl3" ref-type="table">Table 3</xref>).<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Change in cerebrovascular blood flow (&#916;rCBF) in the bilateral striatum upon administration of the dopamine D<sub>2/3</sub>R agonist apomorphine as a function of the mean [<sup>18</sup>F]FP BP<sub>ND</sub> in the group of nine healthy participants.</p></caption><alt-text id="alttext0020">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig><table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>Correlation of dopamine D<sub>2/3</sub> binding potential (BP<sub>ND</sub>) and apomorphine-induced perfusion changes of the bilateral regions of interest (ROI) striatum, caudate nucleus (CN), putamen (Put), thalamus (Thal) and inferior temporal cortex (ITC) in healthy controls (N&#160;=&#160;9)). P-values for the regions specified in the primary hypothesis are presented both with (p<sub>FDR</sub>) and without (p<sub>uncorrected</sub>) multiple comparison corrections, using the Benjamini and Hochberg method (<xref rid="bib3" ref-type="bibr">Benjamini and Hochberg, 1995</xref>). Statistically significant values are marked with an asterisk (&#8727;).</p></caption><alt-text id="alttext0035">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">ROI</th><th colspan="1" rowspan="1"><italic toggle="yes">r</italic></th><th colspan="1" rowspan="1">p<sub>FDR</sub></th><th colspan="1" rowspan="1">p<sub>uncorrected</sub></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><bold>Striatum</bold></td><td align="left" colspan="1" rowspan="1">&#8722;0.71</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.033&#8727;</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>CN</bold></td><td align="left" colspan="1" rowspan="1">&#8722;0.64</td><td align="left" colspan="1" rowspan="1">0.008&#8727;</td><td align="left" colspan="1" rowspan="1">0.004</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Put</bold></td><td align="left" colspan="1" rowspan="1">&#8722;0.07</td><td align="left" colspan="1" rowspan="1">0.787</td><td align="left" colspan="1" rowspan="1">0.787</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Thal</bold></td><td align="left" colspan="1" rowspan="1">&#8722;0.66</td><td align="left" colspan="1" rowspan="1">0.008&#8727;</td><td align="left" colspan="1" rowspan="1">0.003</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>ITC</bold></td><td align="left" colspan="1" rowspan="1">0.20</td><td align="left" colspan="1" rowspan="1">0.787</td><td align="left" colspan="1" rowspan="1">0.603</td></tr></tbody></table></table-wrap></p></sec><sec id="sec3.4"><label>3.4</label><title>Apomorphine-induced cardiovascular and global gCBF effects</title><p id="p0130">Previous studies have reported varying apomorphine-associated effects on heart rate and blood pressure (<xref rid="bib44" ref-type="bibr">Rowbotham et al., 1983</xref>), or no changes of heart rate or blood pressure at all (<xref rid="bib19" ref-type="bibr">Fagan et al., 2001</xref>; <xref rid="bib55" ref-type="bibr">Stocchi et al., 2022</xref>). Comparison of mean heart and respiration rates at baseline and after apomorphine challenge (paired t-tests) showed no effect of treatment on heart rate (p&#160;=&#160;0.50) or respiration rate (p&#160;=&#160;0.46) (see <xref rid="appsec1" ref-type="sec">Supplementary Fig. 1</xref>).</p><p id="p0135">Comparison of global gCBF at baseline and after apomorphine challenge (paired t-tests) showed also no effect of treatment (p&#160;=&#160;0.64).</p></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p id="p0140">Our combined pharmaco-PET/fMRI study with apomorphine challenge in healthy subjects reveals neurovascular coupling of nigrostriatal dopamine system and local hemodynamic activity. In our study population of nine healthy participants, higher baseline D<sub>2/3</sub> receptor availability predicted a lesser hemodynamic response in striatum.</p><sec id="sec4.1"><label>4.1</label><title>[<sup>18</sup>F]FP BP<sub>ND</sub> in healthy subjects</title><p id="p0145">Our analysis of dynamic [<sup>18</sup>F]FP PET data during the first 196&#160;min of the recording indicated a BP<sub>ND</sub> of 46.9&#160;&#177;&#160;4.0 in bilateral striatum of healthy subjects, which exceeds our earlier estimates without PVC (e.g., 21.6&#160;&#177;&#160;4.3 (<xref rid="bib13" ref-type="bibr">Cumming et al., 2013</xref>), 16.8&#160;&#177;&#160;3.0 (<xref rid="bib41" ref-type="bibr">Rominger et al., 2012</xref>); for estimates of [<sup>18</sup>F]FP BP<sub>ND</sub> without PVC, see <xref rid="appsec1" ref-type="sec">Supplementary Table 2</xref>). Indeed, mouse dissection studies confirmed the substantial spillover of [<sup>18</sup>F]FP PET signal from striatum (<xref rid="bib40" ref-type="bibr">Rominger et al., 2010</xref>). While PVC effects are naturally less pronounced at the scale of human striatum, present results with application of a PVC algorithm (<xref rid="bib42" ref-type="bibr">Rousset et al., 1998</xref>, <xref rid="bib43" ref-type="bibr">2000</xref>) are in general accord with earlier reports of [<sup>18</sup>F]FP BP<sub>ND</sub> in PV-corrected striatum (39.1&#160;&#177;&#160;7.0 (<xref rid="bib31" ref-type="bibr">Kegeles et al., 2008</xref>); 33.0&#160;&#177;&#160;4.9 (<xref rid="bib50" ref-type="bibr">Seaman et al., 2019</xref>)). Our PVC BP<sub>ND</sub> findings in thalamus (3.18&#160;&#177;&#160;0.46) and ITC (1.87&#160;&#177;&#160;0.45) are likewise in agreement with the earlier PVC results in healthy humans (<xref rid="bib31" ref-type="bibr">Kegeles et al., 2008</xref>; <xref rid="bib50" ref-type="bibr">Seaman et al., 2019</xref>). While striatal dopamine D<sub>2/3</sub>R availability declines substantially with healthy aging (<xref rid="bib61" ref-type="bibr">Wong et al., 1984</xref>), we did not see any significant decline with age in the present sample aged 24&#8211;49 years.</p></sec><sec id="sec4.2"><label>4.2</label><title>Global apomorphine-induced rCBF changes</title><p id="p0150">In this study, the administration of the dopamine D<sub>2/3</sub>R-prefering full agonist apomorphine (mean dose 0.73&#160;mg, i.e. 0.01&#160;mg/kg) did not increase rCBF in the bilateral striatum, possibly due to high intra-individual variability of rCBF changes. In several earlier imaging studies (mainly in clinical populations) pharmacological challenges with dopamine agonists, and also antagonists, acutely stimulated rCBF in striatum and certain cortical regions (<xref rid="bib10" ref-type="bibr">Chen et al., 2015</xref>; <xref rid="bib20" ref-type="bibr">Fern&#225;ndez-Seara et al., 2011</xref>; <xref rid="bib26" ref-type="bibr">Handley et al., 2013</xref>; <xref rid="bib32" ref-type="bibr">Kobari et al., 1995</xref>; <xref rid="bib37" ref-type="bibr">Mu et al., 2007</xref>; <xref rid="bib49" ref-type="bibr">Schouw et al., 2013</xref>). In particular, Sabatini et al. found that apomorphine challenge (mean dose 0.3&#160;mg) induced a widespread 12% increase in cerebral perfusion in Parkinson's disease patients (<xref rid="bib45" ref-type="bibr">Sabatini et al., 1991</xref>). They proposed that extra-cerebrovascular dopamine receptors mediated this effect, based on their additional observation that pretreatment with the peripherally acting dopamine antagonist domperidone (60&#160;mg, p. o.) blocked the perfusion increase. However, we note that the exclusively peripheral action of domperidone has been called into question (<xref rid="bib21" ref-type="bibr">Ferrier, 2014</xref>). In a recent ASL study, challenge with the D<sub>2/3</sub>R partial agonist and 5HT<sub>2A</sub> antagonist aripiprazole increased rCBF in striatum by 8% in first episode psychosis patients, with no such effects in their healthy control group (<xref rid="bib4" ref-type="bibr">Bojesen et al., 2023</xref>). Such findings may represent sensitization of dopamine agonist responses in untreated patients with Parkinson's disease or untreated schizophrenia. Indeed, in a rat study using [<sup>14</sup>C]iodoantipyrine autoradiographic method, unilateral lesioning of the nigrostriatal dopamine pathway potentiated the apomorphine-induced rCBF increase (<xref rid="bib27" ref-type="bibr">Ingvar et al., 1983</xref>).</p><p id="p0155">Bojesen et al. reported no effect of the partial agonist on rCBF in their healthy control group (<xref rid="bib4" ref-type="bibr">Bojesen et al., 2023</xref>). We report that the full dopamine D<sub>2/3</sub>R-preferring agonist apomorphine exhibits high intra-individual variability in rCBF among healthy human subjects, with a 9.3% increase in bilateral caudate nucleus activity. However, this increase did not survive correction for multiple comparisons (p<sub>uncorrected</sub>&#160;=&#160;0.027; p<sub>FDR</sub>&#160;=&#160;0.11). Given the small sample size as well as the high intra-individual variability in baseline and &#916;<funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000928</institution-id><institution>CBF</institution></institution-wrap></funding-source> values (see <xref rid="fig2" ref-type="fig">Fig. 2</xref>), we suppose that a larger sample size might support stronger claims about possible perfusion changes in other brain regions. Thus, further studies are required e.g. to validate extra-striatal effects.</p></sec><sec id="sec4.3"><label>4.3</label><title>Global apomorphine-induced rCBF changes correlate with the [<sup>18</sup>F]FA BP<sub>ND</sub></title><p id="p0160">Even though single subjects did not show systematic hemodynamic effects of the apomorphine on striatal rCBF, the single-subject trajectories could be predicted by the [<sup>18</sup>F]FA BP<sub>ND</sub>. To evaluate the association of [<sup>18</sup>F]FA BP<sub>ND</sub> and the respective hemodynamic effect of apomorphine challenge, we calculated the correlation of [<sup>18</sup>F]FA BP<sub>ND</sub> and apomorphine-induced rCBF changes in our group of healthy participants. There was a significant negative correlation (r&#160;=&#160;&#8722;0.71, p<sub>uncorrected</sub>&lt;0.05) between baseline [<sup>18</sup>F]FA BP<sub>ND</sub> in the bilateral striatum and the corresponding rCBF changes evoked by apomorphine challenge. Exploratory analysis revealed a negative correlation in thalamus (p<sub>PVC</sub>&lt;0.003), but not in ITC. The negative coupling of D<sub>2/3</sub>R BP<sub>ND</sub> and apomorphine-induced rCBF changes in striatal regions reported herein suggests that pharmacodynamic response to apomorphine depends on baseline D<sub>2/3</sub>R availability.</p><p id="p0165">We confined our investigation to effects of dopamine agonism, whereas others have reported on perfusion effects of receptor antagonism. In a PET/MRI study in non-human primates, administration of non-tracer mass doses of the dopamine D<sub>2/3</sub>R antagonist [<sup>11</sup>C]raclopride increased striatal rCBF in ASL (<xref rid="bib46" ref-type="bibr">Sander et al., 2013</xref>). Similarly, in human ASL studies, acute treatment with antipsychotic medications (i.e., D<sub>2/3</sub>R antagonists) increased rCBF. In particular, challenge with metoclopramide (10&#160;mg, p. o.) increased rCBF in the striatum and thalamus in healthy volunteers (<xref rid="bib20" ref-type="bibr">Fern&#225;ndez-Seara et al., 2011</xref>). In a recent study, haloperidol (3&#160;mg, p. o.) and risperidone (0.5 and 2&#160;mg, p. o.) both increased striatal rCBF in healthy volunteers as compared to placebo treatment (<xref rid="bib51" ref-type="bibr">Selvaggi et al., 2019</xref>).</p><p id="p0170">Thus, a compilation of present literature results with pharmacological challenge show that D<sub>2/3</sub>R agonists and antagonists both increased cerebral perfusion. This phenomenon implies a U-shaped relationship between rCBF and dopamine receptor activation. Such a relationship may have some bearing on the present finding that individuals with lowest striatal [<sup>18</sup>F]FA BP<sub>ND</sub> showed the greatest changes in rCBF after apomorphine challenge (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). We suppose that tonic dopamine signaling may be poised in healthy individuals such that there is a bimodal hemodynamic response to apomorphine challenge. Acting as an autoreceptor agonist, apomorphine (2&#8211;4&#160;mg) inhibited the release of endogenous dopamine in the [<sup>11</sup>C]raclopride PET competition paradigm (<xref rid="bib14" ref-type="bibr">de La Fuente-et al., 2001</xref>). Conceivably, the individuals with low striatal [<sup>18</sup>F]FP BP<sub>ND</sub> in the present study may have high occupancy by endogenous dopamine, making them more sensitive to autoreceptor activation by the present apomorphine challenge. In this scenario, individual differences in autoreceptor tonus may have contributed to the variable hemodynamic responses in the present study group.</p><p id="p0175">Although the pathway for hemodynamic responses to pharmacological challenges remains uncertain, present results in healthy individuals are pertinent to the concept of individualized medicine. Thus, responses in a given individual depend upon their particular state of dopaminergic signaling. Similarly, we have seen that neurochemical responses to challenge with antipsychotic medication depend upon baseline D<sub>2/3</sub> receptor availability. Furthermore, prolonged treatment with antipsychotic medication can increase receptor binding (<xref rid="bib53" ref-type="bibr">Silvestri et al., 2000</xref>), which might propagate to hemodynamic changes, perhaps as a marker for the emergence of receptor supersensitivity (<xref rid="bib11" ref-type="bibr">Chouinard et al., 2017</xref>). Extension of present methods might illuminate the basis of dopaminergic supersensitivity as an emergent phenomenon upon repeated amphetamine administration in healthy controls and as a trait marker in patients with schizophrenia (<xref rid="bib60" ref-type="bibr">Weidenauer et al., 2020</xref>).</p></sec><sec id="sec4.4"><label>4.4</label><title>Limitations</title><p id="p0180">The small sample size of the group limits the power of detecting ROI-specific interaction effects, especially in extra-striatal regions of interest. Further exploration of the dose-dependence of hemodynamic responses to apomorphine in a larger population could validate our conjecture of a U-shaped relationship between hemodynamic response and the balance between dopamine D<sub>2/3</sub> agonist and antagonist effects.</p><p id="p0185">Due to the small sample size, the study has a higher risk of type II errors, where actual effects might go undetected. This limitation also makes the results less generalizable to broader populations. A larger sample could provide more robust evidence and allow for a more accurate analysis of dose-dependent effects, such as the hypothesized U-shaped relationship between hemodynamic responses to apomorphine and dopamine D<sub>2/3</sub>R BP<sub>ND</sub>.</p></sec></sec><sec id="sec5"><title>Author contributions</title><p id="p0190">CNS, XMH and GG designed the research. XMH, JR, CS and MS recruited the participants. CS, XMH, MS, JR, KB and GO performed the research. GO and RB provided technical support and implemented the experimental setup. CS, JR and IL analyzed the data. CNS, MS, PC, and GG wrote the manuscript with input from all other authors. All authors gave final approval to the manuscript.</p></sec><sec id="sec6"><title>Funding</title><p id="p0195">Financial support for this work was provided by the department of Molecular Neuroimaging at the <funding-source id="gs4">Central Institute of Mental Health Mannheim (CIMH)</funding-source>.</p></sec><sec id="sec7"><title>Competing interest</title><p id="p0200">None to report.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of competing interest</title><p id="p0210">No potential competing interests to report.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Agbo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Crass</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Chapel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Galluppi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Blum</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease</article-title><source>Clin Transl Sci</source><volume>14</volume><issue>4</issue><year>2021</year><fpage>1464</fpage><lpage>1475</lpage><pub-id pub-id-type="pmid">33650272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cts.13008</pub-id><pub-id pub-id-type="pmcid">PMC8301595</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Alsop</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Detre</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Golay</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gunther</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hendrikse</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hernandez-Garcia</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia</article-title><source>Magn. Reson. Med.</source><volume>73</volume><issue>1</issue><year>2015</year><fpage>102</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">24715426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrm.25197</pub-id><pub-id pub-id-type="pmcid">PMC4190138</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Benjamini</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hochberg</surname><given-names>Y.</given-names></name></person-group><article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title><source>J. Roy. Stat. Soc.</source><volume>57</volume><year>1995</year><fpage>289</fpage><lpage>300</lpage><comment>B</comment></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Bojesen</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Glenth&#248;j</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Sigvard</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Tangmose</surname><given-names>K.</given-names></name><name name-style="western"><surname>Raghava</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Ebdrup</surname><given-names>B.H.</given-names></name><etal/></person-group><article-title>Cerebral blood flow in striatum is increased by partial dopamine agonism in initially antipsychotic-na&#239;ve patients with psychosis</article-title><source>Psychol. Med.</source><volume>53</volume><issue>14</issue><year>2023</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0033291723000144</pub-id><pub-id pub-id-type="pmcid">PMC10600821</pub-id><pub-id pub-id-type="pmid">36754993</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Bruinsma</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Sarma</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Worrell</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>The relationship between dopamine neurotransmitter dynamics and the blood-oxygen-level-dependent (BOLD) signal: a review of pharmacological functional magnetic resonance imaging</article-title><source>Front. Neurosci.</source><volume>12</volume><year>2018</year><fpage>238</fpage><pub-id pub-id-type="pmid">29692706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2018.00238</pub-id><pub-id pub-id-type="pmcid">PMC5902685</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Calabro</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Montez</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Laymon</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Foran</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hallquist</surname><given-names>M.N.</given-names></name><etal/></person-group><article-title>Striatal dopamine supports reward expectation and learning: a simultaneous PET/fMRI study</article-title><source>Neuroimage</source><volume>267</volume><year>2023</year><object-id pub-id-type="publisher-id">119831</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2022.119831</pub-id><pub-id pub-id-type="pmcid">PMC9983071</pub-id><pub-id pub-id-type="pmid">36586541</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Caravaggio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Porco</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Torres-Carmona</surname><given-names>E.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>E.</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Measuring amphetamine-induced dopamine release in humans: a comparative meta-analysis of [(11) C]-raclopride and [(11) C]-(+)-PHNO studies</article-title><source>Synapse</source><volume>75</volume><issue>5</issue><year>2021</year><object-id pub-id-type="publisher-id">e22195</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/syn.22195</pub-id><pub-id pub-id-type="pmid">33471400</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Chappell</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Groves</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Whitcher</surname><given-names>B.</given-names></name><name name-style="western"><surname>Woolrich</surname><given-names>M.W.</given-names></name></person-group><article-title>IEEE transactions on signal processing</article-title><volume>57</volume><year>2009</year><fpage>223</fpage><lpage>236</lpage></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Chappell</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Groves</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>MacIntosh</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Donahue</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Jezzard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Woolrich</surname><given-names>M.W.</given-names></name></person-group><article-title>Partial volume correction of multiple inversion time arterial spin labeling MRI data</article-title><source>Magn. Reson. Med.</source><volume>65</volume><issue>4</issue><year>2011</year><fpage>1173</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">21337417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrm.22641</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pressman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Simuni</surname><given-names>T.</given-names></name><name name-style="western"><surname>Parrish</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Gitelman</surname><given-names>D.R.</given-names></name></person-group><article-title>Effects of acute levodopa challenge on resting cerebral blood flow in Parkinson's Disease patients assessed using pseudo-continuous arterial spin labeling</article-title><source>PeerJ</source><volume>3</volume><year>2015</year><object-id pub-id-type="publisher-id">e1381</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7717/peerj.1381</pub-id><pub-id pub-id-type="pmcid">PMC4699782</pub-id><pub-id pub-id-type="pmid">26734502</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Chouinard</surname><given-names>G.</given-names></name><name name-style="western"><surname>Samaha</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Chouinard</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Peretti</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Kanahara</surname><given-names>N.</given-names></name><name name-style="western"><surname>Takase</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy</article-title><source>Psychother. Psychosom.</source><volume>86</volume><issue>4</issue><year>2017</year><fpage>189</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">28647739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000477313</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="book" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Cumming</surname><given-names>P.</given-names></name></person-group><part-title>Imaging Dopamine</part-title><year>2009</year><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge</publisher-loc></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Cumming</surname><given-names>P.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>G.</given-names></name><name name-style="western"><surname>la Foug&#232;re</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rominger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bartenstein</surname><given-names>P.</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>H.G.</given-names></name><etal/></person-group><article-title>Surrogate markers for cerebral blood flow correlate with [<sup>1</sup>&#8312;F]-fallypride binding potential at dopamine D(2/3) receptors in human striatum</article-title><source>Synapse</source><volume>67</volume><issue>4</issue><year>2013</year><fpage>199</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">23239525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/syn.21630</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>de La Fuente-Fern&#225;ndez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Sossi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Holden</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Calne</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Ruth</surname><given-names>T.J.</given-names></name><etal/></person-group><article-title>Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition</article-title><source>J. Cerebr. Blood Flow Metabol.</source><volume>21</volume><issue>10</issue><year>2001</year><fpage>1151</fpage><lpage>1159</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00004647-200110000-00003</pub-id><pub-id pub-id-type="pmid">11598492</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Deutschl&#228;nder</surname><given-names>A.</given-names></name><name name-style="western"><surname>la Foug&#232;re</surname><given-names>C.</given-names></name><name name-style="western"><surname>Boetzel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Gildehaus</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Bartenstein</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients</article-title><source>Neuroimage Clin</source><volume>12</volume><year>2016</year><fpage>41</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">27408789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2016.06.007</pub-id><pub-id pub-id-type="pmcid">PMC4925448</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Dhall</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kreitzman</surname><given-names>D.L.</given-names></name></person-group><article-title>Advances in levodopa therapy for Parkinson disease: review of RYTARY (carbidopa and levodopa) clinical efficacy and safety</article-title><source>Neurology</source><volume>86</volume><issue>14 Suppl. 1</issue><year>2016</year><fpage>S13</fpage><lpage>S24</lpage><pub-id pub-id-type="pmid">27044646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000002510</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Diedrichsen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maderwald</surname><given-names>S.</given-names></name><name name-style="western"><surname>K&#252;per</surname><given-names>M.</given-names></name><name name-style="western"><surname>Th&#252;rling</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gizewski</surname><given-names>E.R.</given-names></name><etal/></person-group><article-title>Imaging the deep cerebellar nuclei: a probabilistic atlas and normalization procedure</article-title><source>Neuroimage</source><volume>54</volume><issue>3</issue><year>2011</year><fpage>1786</fpage><lpage>1794</lpage><pub-id pub-id-type="pmid">20965257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2010.10.035</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Efthimiou</surname><given-names>O.</given-names></name><name name-style="western"><surname>Taipale</surname><given-names>H.</given-names></name><name name-style="western"><surname>Radua</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schneider-Thoma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pinz&#243;n-Espinosa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ortu&#241;o</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data</article-title><source>Lancet Psychiatr.</source><volume>11</volume><issue>2</issue><year>2024</year><fpage>102</fpage><lpage>111</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(23)00366-8</pub-id><pub-id pub-id-type="pmid">38215784</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Fagan</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Buttler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marbury</surname><given-names>T.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Edmonds</surname><given-names>A.</given-names></name></person-group><article-title>Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates</article-title><source>Am. J. Cardiol.</source><volume>88</volume><issue>7</issue><year>2001</year><fpage>760</fpage><lpage>766</lpage><pub-id pub-id-type="pmid">11589843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0002-9149(01)01847-1</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez-Seara</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Azn&#225;rez-Sanado</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mengual</surname><given-names>E.</given-names></name><name name-style="western"><surname>Irigoyen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heukamp</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pastor</surname><given-names>M.A.</given-names></name></person-group><article-title>Effects on resting cerebral blood flow and functional connectivity induced by metoclopramide: a perfusion MRI study in healthy volunteers</article-title><source>Br. J. Pharmacol.</source><volume>163</volume><issue>8</issue><year>2011</year><fpage>1639</fpage><lpage>1652</lpage><pub-id pub-id-type="pmid">21175574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1476-5381.2010.01161.x</pub-id><pub-id pub-id-type="pmcid">PMC3166692</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Ferrier</surname><given-names>J.</given-names></name></person-group><article-title>Domperidone as an unintended antipsychotic</article-title><source>Can. Pharm. J.</source><volume>147</volume><issue>2</issue><year>2014</year><fpage>76</fpage><lpage>77</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1715163514521969</pub-id><pub-id pub-id-type="pmcid">PMC3962062</pub-id><pub-id pub-id-type="pmid">24660005</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Goldstein</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Seidman</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Makris</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ahern</surname><given-names>T.</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Caviness</surname><given-names>V.S.</given-names><suffix>Jr.</suffix></name><etal/></person-group><article-title>Hypothalamic abnormalities in schizophrenia: sex effects and genetic vulnerability</article-title><source>Biol. Psychiatr.</source><volume>61</volume><issue>8</issue><year>2007</year><fpage>935</fpage><lpage>945</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2006.06.027</pub-id><pub-id pub-id-type="pmid">17046727</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Groves</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Woolrich</surname><given-names>M.W.</given-names></name></person-group><article-title>Combined spatial and non-spatial prior for inference on MRI time-series</article-title><source>Neuroimage</source><volume>45</volume><issue>3</issue><year>2009</year><fpage>795</fpage><lpage>809</lpage><pub-id pub-id-type="pmid">19162204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2008.12.027</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Gr&#252;nder</surname><given-names>G.</given-names></name><name name-style="western"><surname>Siessmeier</surname><given-names>T.</given-names></name><name name-style="western"><surname>Piel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vernaleken</surname><given-names>I.</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride</article-title><source>J. Nucl. Med.</source><volume>44</volume><issue>1</issue><year>2003</year><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">12515884</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>H.</given-names></name><name name-style="western"><surname>Halldin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dijkstra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wikstr&#246;m</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wise</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Pugsley</surname><given-names>T.A.</given-names></name><etal/></person-group><article-title>Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907</article-title><source>Psychopharmacology (Berl)</source><volume>128</volume><issue>3</issue><year>1996</year><fpage>240</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">8972543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002130050131</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Handley</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zelaya</surname><given-names>F.O.</given-names></name><name name-style="western"><surname>Reinders</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>O'Gorman</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain</article-title><source>Hum. Brain Mapp.</source><volume>34</volume><issue>2</issue><year>2013</year><fpage>272</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">22451196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.21436</pub-id><pub-id pub-id-type="pmcid">PMC6870199</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Ingvar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lindvall</surname><given-names>O.</given-names></name><name name-style="western"><surname>Stenevi</surname><given-names>U.</given-names></name></person-group><article-title>Apomorphine-induced changes in local cerebral blood flow in normal rats and after lesions of the dopaminergic nigrostriatal bundle</article-title><source>Brain Res.</source><volume>262</volume><issue>2</issue><year>1983</year><fpage>259</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">6404503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-8993(83)91016-8</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Ishibashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Mandelkern</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>London</surname><given-names>E.D.</given-names></name></person-group><article-title>The simplified reference tissue model with 18F-fallypride positron emission tomography: choice of reference region</article-title><source>Mol. Imag.</source><volume>12</volume><issue>8</issue><year>2013</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.2310/7290.2013.00065</pub-id><pub-id pub-id-type="pmcid">PMC4103900</pub-id><pub-id pub-id-type="pmid">24447617</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Jauhar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Veronese</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rogdaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bloomfield</surname><given-names>M.</given-names></name><name name-style="western"><surname>Natesan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Turkheimer</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Regulation of dopaminergic function: an [(18)F]-DOPA PET apomorphine challenge study in humans</article-title><source>Transl. Psychiatry</source><volume>7</volume><issue>2</issue><year>2017</year><object-id pub-id-type="publisher-id">e1027</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/tp.2016.270</pub-id><pub-id pub-id-type="pmcid">PMC5438020</pub-id><pub-id pub-id-type="pmid">28170002</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Jenner</surname><given-names>P.</given-names></name><name name-style="western"><surname>Katzenschlager</surname><given-names>R.</given-names></name></person-group><article-title>Apomorphine - pharmacological properties and clinical trials in Parkinson's disease</article-title><source>Parkinsonism Relat. Disorders</source><volume>33</volume><issue>Suppl. 1</issue><year>2016</year><fpage>S13</fpage><lpage>s21</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2016.12.003</pub-id><pub-id pub-id-type="pmid">27979722</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Kegeles</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Slifstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frankle</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hackett</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride</article-title><source>Neuropsychopharmacology</source><volume>33</volume><issue>13</issue><year>2008</year><fpage>3111</fpage><lpage>3125</lpage><pub-id pub-id-type="pmid">18418366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npp.2008.33</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Kobari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fukuuchi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shinohara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Obara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nogawa</surname><given-names>S.</given-names></name></person-group><article-title>Levodopa-induced local cerebral blood flow changes in Parkinson's disease and related disorders</article-title><source>J. Neurol. Sci.</source><volume>128</volume><issue>2</issue><year>1995</year><fpage>212</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">7738597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0022-510x(94)00237-i</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Lammertsma</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Hume</surname><given-names>S.P.</given-names></name></person-group><article-title>Simplified reference tissue model for PET receptor studies</article-title><source>Neuroimage</source><volume>4</volume><issue>3 Pt 1</issue><year>1996</year><fpage>153</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">9345505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/nimg.1996.0066</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Lohani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Poplawsky</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Moghaddam</surname><given-names>B.</given-names></name></person-group><article-title>Unexpected global impact of VTA dopamine neuron activation as measured by opto-fMRI</article-title><source>Mol. Psychiatr.</source><volume>22</volume><issue>4</issue><year>2017</year><fpage>585</fpage><lpage>594</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mp.2016.102</pub-id><pub-id pub-id-type="pmcid">PMC5269559</pub-id><pub-id pub-id-type="pmid">27457809</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Martinez-M&#246;ller</surname><given-names>A.</given-names></name><name name-style="western"><surname>Souvatzoglou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Delso</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bundschuh</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Chefd'hotel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>S.I.</given-names></name><etal/></person-group><article-title>Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data</article-title><source>J. Nucl. Med.</source><volume>50</volume><issue>4</issue><year>2009</year><fpage>520</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">19289430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.108.054726</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Millan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Maiofiss</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cussac</surname><given-names>D.</given-names></name><name name-style="western"><surname>Audinot</surname><given-names>V.</given-names></name><name name-style="western"><surname>Boutin</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Newman-Tancredi</surname><given-names>A.</given-names></name></person-group><article-title>Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes</article-title><source>J. Pharmacol. Exp. Therapeut.</source><volume>303</volume><issue>2</issue><year>2002</year><fpage>791</fpage><lpage>804</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.102.039867</pub-id><pub-id pub-id-type="pmid">12388666</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Mu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Grenesko</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Molnar</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>B.</given-names></name><etal/></person-group><article-title>A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia</article-title><source>Schizophr. Res.</source><volume>94</volume><issue>1&#8211;3</issue><year>2007</year><fpage>332</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">17596915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.schres.2007.03.033</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Brownell</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Iris Chen</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Livni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>B.R.</given-names></name><etal/></person-group><article-title>Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET</article-title><source>Synapse</source><volume>36</volume><issue>1</issue><year>2000</year><fpage>57</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">10700026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1098-2396(200004)36:1&lt;57::AID-SYN6&gt;3.0.CO;2-K</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Olsson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Halldin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Farde</surname><given-names>L.</given-names></name></person-group><article-title>Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET</article-title><source>Neuroimage</source><volume>22</volume><issue>2</issue><year>2004</year><fpage>794</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">15193608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2004.02.002</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Rominger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mille</surname><given-names>E.</given-names></name><name name-style="western"><surname>B&#246;ning</surname><given-names>G.</given-names></name><name name-style="western"><surname>Esmaeilzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>W&#228;ngler</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Endogenous competition against binding of [(18)F]DMFP and [(18)F]fallypride to dopamine D(2/3) receptors in brain of living mouse</article-title><source>Synapse</source><volume>64</volume><issue>4</issue><year>2010</year><fpage>313</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">19957365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/syn.20730</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Rominger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cumming</surname><given-names>P.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Koller</surname><given-names>G.</given-names></name><name name-style="western"><surname>B&#246;ning</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wulff</surname><given-names>M.</given-names></name><etal/></person-group><article-title>[18F]Fallypride PET measurement of striatal and extrastriatal dopamine D 2/3 receptor availability in recently abstinent alcoholics</article-title><source>Addiction Biol.</source><volume>17</volume><issue>2</issue><year>2012</year><fpage>490</fpage><lpage>503</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1369-1600.2011.00355.x</pub-id><pub-id pub-id-type="pmid">22023291</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Rousset</surname><given-names>O.G.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>A.C.</given-names></name></person-group><article-title>Correction for partial volume effects in PET: principle and validation</article-title><source>J. Nucl. Med.</source><volume>39</volume><issue>5</issue><year>1998</year><fpage>904</fpage><lpage>911</lpage><pub-id pub-id-type="pmid">9591599</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Rousset</surname><given-names>O.G.</given-names></name><name name-style="western"><surname>Deep</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kuwabara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Gjedde</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Cumming</surname><given-names>P.</given-names></name></person-group><article-title>Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects</article-title><source>Synapse</source><volume>37</volume><issue>2</issue><year>2000</year><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">10881028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1098-2396(200008)37:2&lt;81::AID-SYN1&gt;3.0.CO;2-#</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Rowbotham</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Keil</surname><given-names>L.C.</given-names></name></person-group><article-title>Failure of naloxone to reverse apomorphine effects in humans</article-title><source>Psychoneuroendocrinology</source><volume>8</volume><issue>1</issue><year>1983</year><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">6308702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0306-4530(83)90045-8</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Sabatini</surname><given-names>U.</given-names></name><name name-style="western"><surname>Rascol</surname><given-names>O.</given-names></name><name name-style="western"><surname>Celsis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Houin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rascol</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marc-Vergnes</surname><given-names>J.P.</given-names></name><etal/></person-group><article-title>Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms</article-title><source>Br. J. Clin. Pharmacol.</source><volume>32</volume><issue>2</issue><year>1991</year><fpage>229</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">1931472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1991.tb03886.x</pub-id><pub-id pub-id-type="pmcid">PMC1368448</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Sander</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Hooker</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Catana</surname><given-names>C.</given-names></name><name name-style="western"><surname>Normandin</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Alpert</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Knudsen</surname><given-names>G.M.</given-names></name><etal/></person-group><article-title>Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>110</volume><issue>27</issue><year>2013</year><fpage>11169</fpage><lpage>11174</lpage><pub-id pub-id-type="pmid">23723346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1220512110</pub-id><pub-id pub-id-type="pmcid">PMC3703969</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Sander</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Wey</surname><given-names>H.Y.</given-names></name></person-group><article-title>Advances in simultaneous PET/MR for imaging neuroreceptor function</article-title><source>J. Cerebr. Blood Flow Metabol.</source><volume>40</volume><issue>6</issue><year>2020</year><fpage>1148</fpage><lpage>1166</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0271678X20910038</pub-id><pub-id pub-id-type="pmcid">PMC7238372</pub-id><pub-id pub-id-type="pmid">32169011</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Scarselli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Armogida</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pardini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chiacchio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Corsini</surname><given-names>G.U.</given-names></name></person-group><article-title>Apomorphine. A novel effect for an old compound</article-title><source>Adv. Neurol.</source><volume>86</volume><year>2001</year><fpage>367</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">11553998</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Schouw</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Kaag</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Caan</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Heijtel</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Majoie</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Nederveen</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>Mapping the hemodynamic response in human subjects to a dopaminergic challenge with dextroamphetamine using ASL-based pharmacological MRI</article-title><source>Neuroimage</source><volume>72</volume><year>2013</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23296186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2012.12.056</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Seaman</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Juarez</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Castrellon</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>L.L.</given-names></name><etal/></person-group><article-title>Differential regional decline in dopamine receptor availability across adulthood: linear and nonlinear effects of age</article-title><source>Hum. Brain Mapp.</source><volume>40</volume><issue>10</issue><year>2019</year><fpage>3125</fpage><lpage>3138</lpage><pub-id pub-id-type="pmid">30932295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.24585</pub-id><pub-id pub-id-type="pmcid">PMC6548655</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Selvaggi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hawkins</surname><given-names>P.C.T.</given-names></name><name name-style="western"><surname>Dipasquale</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bertolino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dukart</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Increased cerebral blood flow after single dose of antipsychotics in healthy volunteers depends on dopamine D2 receptor density profiles</article-title><source>Neuroimage</source><volume>188</volume><year>2019</year><fpage>774</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">30553916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2018.12.028</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Sheehan</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Lecrubier</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sheehan</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Amorim</surname><given-names>P.</given-names></name><name name-style="western"><surname>Janavs</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weiller</surname><given-names>E.</given-names></name><etal/></person-group><article-title>The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10</article-title><source>J. Clin. Psychiatry</source><volume>59</volume><issue>Suppl. 20:22&#8211;33</issue><year>1998</year><comment>quiz 34-57</comment><pub-id pub-id-type="pmid">9881538</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Silvestri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seeman</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Negrete</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Houle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shammi</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Remington</surname><given-names>G.J.</given-names></name><etal/></person-group><article-title>Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study</article-title><source>Psychopharmacology</source><volume>152</volume><issue>2</issue><year>2000</year><fpage>174</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">11057521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002130000532</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Slifstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kegeles</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Urban</surname><given-names>N.</given-names></name><name name-style="western"><surname>Castrillon</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride</article-title><source>Synapse</source><volume>64</volume><issue>5</issue><year>2010</year><fpage>350</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">20029833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/syn.20734</pub-id><pub-id pub-id-type="pmcid">PMC2840194</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Stocchi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Peckham</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>De Pandis</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Sciarappa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kleiman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Agbo</surname><given-names>F.</given-names></name><etal/></person-group><article-title>A randomized thorough QT study of apomorphine sublingual film in patients with Parkinson's disease</article-title><source>Clin Pharmacol Drug Dev</source><volume>11</volume><issue>9</issue><year>2022</year><fpage>1068</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">35899977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.1147</pub-id><pub-id pub-id-type="pmcid">PMC9541463</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Vernaleken</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fellows</surname><given-names>C.</given-names></name><name name-style="western"><surname>Janouschek</surname><given-names>H.</given-names></name><name name-style="western"><surname>Br&#246;cheler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Veselinovic</surname><given-names>T.</given-names></name><name name-style="western"><surname>Landvogt</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone)</article-title><source>J. Clin. Psychopharmacol.</source><volume>28</volume><issue>6</issue><year>2008</year><fpage>608</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">19011428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JCP.0b013e31818ba2f6</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Vernaleken</surname><given-names>I.</given-names></name><name name-style="western"><surname>Janouschek</surname><given-names>H.</given-names></name><name name-style="western"><surname>Raptis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hellmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Veselinovic</surname><given-names>T.</given-names></name><name name-style="western"><surname>Br&#246;cheler</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas</article-title><source>Int. J. Neuropsychopharmacol.</source><volume>13</volume><issue>7</issue><year>2010</year><fpage>951</fpage><lpage>960</lpage><pub-id pub-id-type="pmid">20392299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1461145710000374</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Vernaleken</surname><given-names>I.</given-names></name><name name-style="western"><surname>Klomp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moeller</surname><given-names>O.</given-names></name><name name-style="western"><surname>Raptis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nagels</surname><given-names>A.</given-names></name><name name-style="western"><surname>R&#246;sch</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability</article-title><source>Int. J. Neuropsychopharmacol.</source><volume>16</volume><issue>4</issue><year>2013</year><fpage>745</fpage><lpage>754</lpage><pub-id pub-id-type="pmid">22906553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1461145712000764</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Alger</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Gunther</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pope</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Saver</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Multi-delay multi-parametric arterial spin-labeled perfusion MRI in acute ischemic stroke - comparison with dynamic susceptibility contrast enhanced perfusion imaging</article-title><source>Neuroimage Clin</source><volume>3</volume><year>2013</year><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24159561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2013.06.017</pub-id><pub-id pub-id-type="pmcid">PMC3791289</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Weidenauer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sauerzopf</surname><given-names>U.</given-names></name><name name-style="western"><surname>Bartova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nics</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pfaff</surname><given-names>S.</given-names></name><etal/></person-group><article-title>On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D(2/3) receptor agonist radioligand study</article-title><source>Transl. Psychiatry</source><volume>10</volume><issue>1</issue><year>2020</year><fpage>2</fpage><pub-id pub-id-type="pmid">32066718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-019-0681-5</pub-id><pub-id pub-id-type="pmcid">PMC7026156</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>H.N.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Dannals</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Links</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Frost</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Ravert</surname><given-names>H.T.</given-names></name><etal/></person-group><article-title>Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain</article-title><source>Science</source><volume>226</volume><issue>4681</issue><year>1984</year><fpage>1393</fpage><lpage>1396</lpage><pub-id pub-id-type="pmid">6334363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.6334363</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Woods</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Okell</surname><given-names>T.W.</given-names></name></person-group><article-title>A general framework for optimizing arterial spin labeling MRI experiments</article-title><source>Magn. Reson. Med.</source><volume>81</volume><issue>4</issue><year>2019</year><fpage>2474</fpage><lpage>2488</lpage><pub-id pub-id-type="pmid">30588656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrm.27580</pub-id><pub-id pub-id-type="pmcid">PMC6492260</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhuo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>S.X.</given-names></name><name name-style="western"><surname>An</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aguirre</surname><given-names>G.K.</given-names></name><etal/></person-group><article-title>Physiological origin of low-frequency drift in blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI)</article-title><source>Magn. Reson. Med.</source><volume>61</volume><issue>4</issue><year>2009</year><fpage>819</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">19189286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrm.21902</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0220">The following is the Supplementary data to this article.<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0215">We thank the team of technical assistance for their excellent support.</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0225">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.nsa.2024.104094" id="intref0015">https://doi.org/10.1016/j.nsa.2024.104094</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>